Dr Helen Jo is a Respiratory and Sleep Physician at Royal Prince Alfred Hospital, where she works as a senior Staff Specialist. She completed her medical degree through The University of New South Wales and completed a PhD researching “predictors of disease progression in IPF” through The University of Sydney, where she is a Senior Clinical Lecturer. She is part of the Interstitial Lung Disease multidisciplinary team and has been an author on numerous publications and guidelines in ILD. Her other interests include cystic fibrosis, bronchiectasis and pulmonary vascular diseases.

Matt is a pulmonologist, genetic epidemiologist, associate director for the Center for Pulmonary Functional Imaging, and the director of the Interstitial Lung Disease Program at the Brigham and Women's Hospital. He completed medical school at the University of Iowa, residency and chief residency at Virginia Commonwealth University, and a pulmonary fellowship and a Master’s of Public Health at Harvard where he is now an Associate Professor of Medicine. In addition, to caring for patient’s in the Intensive Care Unit, and in the Interstitial Lung Disease Clinic his research has been focused on identifying the factors that will help to diagnose early stages of pulmonary fibrosis. The overarching goal of this work is to target specific groups most likely to progress to pulmonary fibrosis with the hope preventing the more advanced stages of this incurable disease. He is the Principal Investigator or co-Principal Investigator on 3 R01 grants as well as the site-PI on numerous pharmaceutical sponsored clinical trials. This work has helped to change our understanding of early stages of pulmonary fibrosis and has led to the first international guidelines for the recommendation on reporting and following patients with evidence for early stages of this disease. His grants have focused on three main themes including 1) defining the phenotype and risk factors that best help to predict early stages of pulmonary fibrosis and their progression, 2) genetic, genomic, and proteomic analyses that help to demonstrate the most important genes, and pathways associated with early pulmonary fibrosis development, and 3) screening studies to identify early-stage pulmonary fibrosis in families. Dr. Hunninghake’s ultimate goal is to consider targeted interventional efforts to reduce the progression of early stages of pulmonary fibrosis.

Dr Miranda Siemienowicz is a thoracic radiologist at Northern Health in Melbourne. She is chair of the Australian and New Zealand Society of Thoracic Radiology and is the Clinical Lead for the National Lung Cancer Screening Program (NLCSP) for the Royal Australian and New Zealand College of Radiologists. Dr Siemienowicz has an interest in interstitial lung disease and provided radiology interpretation for the 2024 international virtual ILD multidisciplinary meetings hosted by Boehringer Ingelheim (the ASEAN-Korea-ANZ ILD MDD). She sits on the Expert Advisory Committee and the Data Development Working Group for the NLCSP for the Department of Health and Aged Care and is a member of the Lung Cancer Working Party of the Thoracic Society of Australia and New Zealand. At Northern Health, she is CT Clinical Lead and Director of Training.

Dr John Mackintosh is a respiratory and lung transplant physician at The Prince Charles Hospital, Brisbane. John provides a dedicated interstitial lung disease outpatient service and is cochair of the Queensland Statewide Interstitial Lung Disease Multi-Disciplinary Meeting that provides diagnostic and management advice to physicians across Australia.

Associate Professor Lauren Troy is a Respiratory Staff Specialist at Royal Prince Alfred Hospital, Visiting Medical Officer at Chris O’Brien Lifehouse, Clinical Associate Professor with the University of Sydney Medical School, and Co-Director of the RPA Institute for Academic Medicine. Her interests are in ILD, respiratory infection, and interventional pulmonology.